跳转至内容
Merck

SML2952

Sigma-Aldrich

Tasisulam

≥98% (HPLC)

别名:

LY 573636, LY-573636, LY573636, N-(2,4-Dichlorobenzoyl)-5-bromothiophene-2-sulfonamide, N-(5-Bromothiophen-2-ylsulfonyl)-2,4-dichlorobenzamide, N-[(5-Bromo-2-thienyl)sulfonyl]-2,4-dichlorobenzamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C11H6BrCl2NO3S2
分子量:
415.11
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
价格与库存信息目前不能提供

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

[S](=O)(=O)(NC(=O)c2c(cc(cc2)Cl)Cl)c1[s]c(cc1)Br

InChI

1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)

InChI 密鑰

WWONFUQGBVOKOF-UHFFFAOYSA-N

生化/生理作用

RNA binding motif protein 39 (RBM39; CAPERα, HCC1) degradation-inducing SPLAM (SPLicing inhibitor sulfonAMide).
Tasisulam (LY573636) is a SPLAM (SPLicing inhibitor sulfonAMide) that bridges RNA binding motif protein 39 (RBM39; CAPERα, HCC1) and DCAF15 for interaction, thereby promoting (CUL4-DDB1-DDA1-DCAF15) E3 ubiquitin ligase complex-mediated RBM39 ubiquitination and subsequent proteasomal degradation. Tasisulam exerts selective toxicity in parental HCT116 cancer cultures (IC50 = 6.5 μM), but not those harboring non-CUL4-DCAF15-associating RBM39 G268V mutant even at a high concentration of 50 μM.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Talin Haritunians et al.
Oncology reports, 20(5), 1237-1242 (2008-10-25)
LY573636-sodium is a promising anti-tumor agent, which causes growth arrest and apoptosis of a variety of human solid tumors in vitro and in vivo. Moreover, studies have shown that the compound is selectively toxic towards tumor cells over their normal
Everett J Perkins et al.
European journal of drug metabolism and pharmacokinetics, 43(3), 355-367 (2017-11-10)
Cytochrome P450 2C9 (CYP2C9) is involved in the biotransformation of many commonly used drugs, and significant drug interactions have been reported for CYP2C9 substrates. Previously published physiologically based pharmacokinetic (PBPK) models of tolbutamide are based on an assumption that its metabolic
Ting Han et al.
Science (New York, N.Y.), 356(6336) (2017-03-18)
Indisulam is an aryl sulfonamide drug with selective anticancer activity. Its mechanism of action and the basis for its selectivity have so far been unknown. Here we show that indisulam promotes the recruitment of RBM39 (RNA binding motif protein 39)
Tyler B Faust et al.
Nature chemical biology, 16(1), 7-14 (2019-11-07)
The investigational drugs E7820, indisulam and tasisulam (aryl-sulfonamides) promote the degradation of the splicing factor RBM39 in a proteasome-dependent mechanism. While the activity critically depends on the cullin RING ligase substrate receptor DCAF15, the molecular details remain elusive. Here we
Timothy Meier et al.
Molecular cancer therapeutics, 10(11), 2168-2178 (2011-09-10)
LY573636-sodium (tasisulam) is a small molecule antitumor agent with a novel mechanism of action currently being investigated in a variety of human cancers. In vitro, tasisulam induced apoptosis via the intrinsic pathway, resulting in cytochrome c release and caspase-dependent cell

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门